Delivery Order SPE2DB20D3103-SPE2DB25FP9G6
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,862.39 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,418.92 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 14, 2025, with an ultimate completion date of August 15, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through...
- The Defense Logistics Agency awarded a $9,133.25 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, representing a short-duration pharmaceutical supply contract. The award carries no set-aside designation, indicating it was competitively awarded through open procurement processes. AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $53,305.92 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and has an ultimate completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a delivery order, this award is a child contract executed under a larger...
- The Defense Logistics Agency awarded a delivery order valued at $9,106.78 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 11, 2025, with an ultimate completion date of August 12, 2025. This is a firm fixed price, non-set-aside contract for pharmaceutical delivery to support federal medical procurement needs. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $10,146.21 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on July 21, 2025, with an ultimate completion date of July 22, 2025. This is a firm fixed price, non-set-aside contract with performance occurring at the contractor's Conshohocken, Pennsylvania facility. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $12,151.38 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injectors on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through...
- The Defense Logistics Agency (DLA) awarded a $16,346.89 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors, with an ultimate completion date of July 28, 2025. This firm fixed-price contract, which was competitively awarded without set-aside designation, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors with a firm fixed price ceiling value of $12,041.74. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The pharmaceutical distributor, headquartered in...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP9G6Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,570.66 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injections on August 18, 2025, with an ultimate completion date of August 19, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $1 billion and runs through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls within AmerisourceBergen's comprehensive pharmaceutical supply mission for the DLA Medical Supply Chain, through which the company delivers brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to support military and veteran healthcare systems. Dupixent is a biologic immunosuppressant used primarily for treating moderate-to-severe eczema, asthma, and other inflammatory conditions, reflecting the company's role as a critical vendor for specialized pharmaceutical products supporting federal medical procurement needs. The order exemplifies the DLA's reliance on AmerisourceBergen as a prime pharmaceutical vendor capable of fulfilling federal medical supply requirements across multiple therapeutic domains through flexible contract vehicles.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.6k | 8/18/25 |